Abstract
The main obstacle to biopharmaceutical delivery in therapeutic concentration into the brain for treating neurological disorders is the presence of the Blood-Brain Barrier (BBB). The physiological process of Receptor-Mediated Transcytosis (RMT) to transport cargo through the brain endothelial cells toward brain parenchyma has prompted researchers to search for non-natural ligands that can be used to transport drugs across the BBB. Conjugation of drugs to RMT ligands would be an effective strategy for its delivery to the central nervous system. An attractive approach to identify novel transcytosing ligands is the screening by phage display combinatorial libraries. The main technology strength lies in the large variety of exogenous peptides or proteins displayed on the phage's surface. Here, we provide a mini-review of phage display technology using in vitro and in vivo BBB models for the development of peptide-mediated drug delivery systems.
Keywords: Phage display technology, blood-brain barrier, drug delivery, shuttle peptides, receptor-mediated transcytosis, molecular trojan horse.
Graphical Abstract
Current Pharmaceutical Biotechnology
Title:Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier
Volume: 22 Issue: 11
Author(s): Viana M. Suárez, Nelson S. Vispo and Oliberto S. Ramos*
Affiliation:
- Department of Pharmacology, School of Biological Sciences, Universidad de Concepcion, Concepcion,Chile
Keywords: Phage display technology, blood-brain barrier, drug delivery, shuttle peptides, receptor-mediated transcytosis, molecular trojan horse.
Abstract: The main obstacle to biopharmaceutical delivery in therapeutic concentration into the brain for treating neurological disorders is the presence of the Blood-Brain Barrier (BBB). The physiological process of Receptor-Mediated Transcytosis (RMT) to transport cargo through the brain endothelial cells toward brain parenchyma has prompted researchers to search for non-natural ligands that can be used to transport drugs across the BBB. Conjugation of drugs to RMT ligands would be an effective strategy for its delivery to the central nervous system. An attractive approach to identify novel transcytosing ligands is the screening by phage display combinatorial libraries. The main technology strength lies in the large variety of exogenous peptides or proteins displayed on the phage's surface. Here, we provide a mini-review of phage display technology using in vitro and in vivo BBB models for the development of peptide-mediated drug delivery systems.
Export Options
About this article
Cite this article as:
Suárez M. Viana, Vispo S. Nelson and Ramos S. Oliberto *, Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier, Current Pharmaceutical Biotechnology 2021; 22 (11) . https://dx.doi.org/10.2174/1389201022666210104115224
DOI https://dx.doi.org/10.2174/1389201022666210104115224 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Activity-dependent Synaptic Plasticity and Metaplasticity in Spinal Motor Networks
Current Pharmaceutical Design Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) Hypothalamic and Neuroendocrine Changes in Huntingtons Disease
Current Drug Targets Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Current Neuropharmacology Editorial [Hot Topic: Regulation of Brain Functions by Adenosine A2A Receptors:Implication for Therapeutics (Executive Editor: Patrizia Popoli) ]
Current Pharmaceutical Design Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology Molecular Hydrogen as a Neuroprotective Agent
Current Neuropharmacology Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Expression Analysis of 4-Hydroxynonenal Modified Proteins in Schizophrenia Brain; Relevance to Involvement in Redox Dysregulation
Current Proteomics Childhood Maltreatment and Stress-Related Psychopathology: The Epigenetic Memory Hypothesis
Current Pharmaceutical Design Role of Polyglycine Repeats in the Regulation of Glycogen Synthase Kinase Activity
Protein & Peptide Letters Axonal Ionic Pathophysiology in Human Peripheral Neuropathy and Motor Neuron Disease
Current Neurovascular Research Indoles and Related Compounds as Cannabinoid Ligands
Mini-Reviews in Medicinal Chemistry NMDA-antagonism (Memantine): An Alternative Pharmacological Therapeutic Principle in Alzheimers and Vascular Dementia
Current Pharmaceutical Design AMPK and its Activator Berberine in the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets Biomarkers and Cellular Signal Detection for Alzheimer’s Disease, Stroke, and Immune System Mediated Disorders
Current Neurovascular Research Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets